---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-035743"
form_type: "8-K"
ticker: "OGEN"
cik: "0001174940"
company_name: "ORAGENICS INC"
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T03:47:27.459760+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Oragenics acquires Odyssey's brain disorder assets for $1M cash and 8M convertible preferred shares

## Summary
- Deal consideration: $1M cash (half due at signing, half at closing or sooner) and 8M shares of Series F Preferred Stock convertible 1:1 into common after shareholder approvals.
- Assets include drug candidates for mild traumatic brain injury (concussion) and Niemann Pick Disease Type C, plus a proprietary powder formulation and nasal delivery device.
- Closing requires Oragenics shareholders to increase authorized common stock from ~4.17M to 350M shares and approve the conversion; Oragenics must also have at least $5M cash at closing.
- Closing expected end of Q4 2023; Oragenics has previously struggled to obtain a quorum at shareholder meetings, creating execution risk.
- Oragenics plans to present the shareholder approvals at its annual meeting scheduled for December 14, 2023.

## SEC filing metadata
- accession: 0001493152-23-035743
- form_type: 8-K
- ticker: OGEN
- cik: 0001174940
- company_name: ORAGENICS INC
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1174940/000149315223035743/0001493152-23-035743-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1174940/000149315223035743/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-035743
- JSON: https://secwatch.observer/filing/0001493152-23-035743.json
- Plain text: https://secwatch.observer/filing/0001493152-23-035743.txt

## Key facts
- Material Agreements
  ORAGENICS INC entered into Purchase Agreement with Odyssey Health, Inc. valued at $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock (effective 2023-10-04).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Odyssey Health, Inc.
  - Value: $1,000,000 in cash and 8,000,000 shares of convertible Series F Preferred Stock
  - Effective: 2023-10-04
  source text: On October 4, 2023, Oragenics, Inc. (the “ Company ”) entered into an Asset Purchase Agreement (the “ Purchase Agreement ”) with Odyssey Health, Inc., f/k/a Odyssey Group International, Inc., a Nevada corporation (“ Odyssey ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1174940/000149315223035743/0001493152-23-035743-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.